John G. McHutchison
Gilead Sciences (United States) · 681 works · 78,043 citations · h-index 124
Top works
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
- Ethical and Scientific Implications of the Globalization of Clinical Research
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- Telaprevir for Previously Treated Chronic HCV Infection
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
- Estimating future hepatitis C morbidity, mortality, and costs in the United States